vs
Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $259.0M, roughly 1.1× ASHFORD HOSPITALITY TRUST INC). ASHFORD HOSPITALITY TRUST INC runs the higher net margin — -26.8% vs -45.7%, a 18.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -6.0%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-86.8M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -7.7%).
Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
AHT vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $259.0M | $281.3M |
| Net Profit | $-69.3M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -2.6% | -43.0% |
| Net Margin | -26.8% | -45.7% |
| Revenue YoY | -6.0% | 39.4% |
| Net Profit YoY | 44.2% | -15.8% |
| EPS (diluted) | $-12.85 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $259.0M | $281.3M | ||
| Q3 25 | $266.1M | $265.2M | ||
| Q2 25 | $302.0M | $232.1M | ||
| Q1 25 | $277.4M | $203.5M | ||
| Q4 24 | $275.5M | $201.8M | ||
| Q3 24 | $276.6M | $191.5M | ||
| Q2 24 | $316.5M | $177.2M | ||
| Q1 24 | $303.9M | $168.5M |
| Q4 25 | $-69.3M | $-128.5M | ||
| Q3 25 | $-60.1M | $-92.7M | ||
| Q2 25 | $-30.4M | $-99.9M | ||
| Q1 25 | $-20.0M | $-95.2M | ||
| Q4 24 | $-124.2M | $-111.0M | ||
| Q3 24 | $-57.9M | $-107.8M | ||
| Q2 24 | $50.3M | $-102.6M | ||
| Q1 24 | $71.6M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -2.6% | -43.0% | ||
| Q3 25 | 4.6% | -37.3% | ||
| Q2 25 | 16.3% | -45.9% | ||
| Q1 25 | 22.2% | -54.6% | ||
| Q4 24 | -17.8% | -62.4% | ||
| Q3 24 | 7.3% | -61.3% | ||
| Q2 24 | 42.8% | -56.8% | ||
| Q1 24 | 50.2% | -59.2% |
| Q4 25 | -26.8% | -45.7% | ||
| Q3 25 | -22.6% | -35.0% | ||
| Q2 25 | -10.1% | -43.0% | ||
| Q1 25 | -7.2% | -46.8% | ||
| Q4 24 | -45.1% | -55.0% | ||
| Q3 24 | -20.9% | -56.3% | ||
| Q2 24 | 15.9% | -57.9% | ||
| Q1 24 | 23.5% | -68.2% |
| Q4 25 | $-12.85 | $-1.01 | ||
| Q3 25 | $-11.35 | $-0.74 | ||
| Q2 25 | $-6.88 | $-0.80 | ||
| Q1 25 | $-4.91 | $-0.77 | ||
| Q4 24 | $-13.64 | $-0.90 | ||
| Q3 24 | $-12.39 | $-0.88 | ||
| Q2 24 | $2.50 | $-0.84 | ||
| Q1 24 | $5.99 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.1M | $378.2M |
| Total DebtLower is stronger | $2.5B | $1.5B |
| Stockholders' EquityBook value | $-626.4M | $-99.3M |
| Total Assets | $2.8B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.1M | $378.2M | ||
| Q3 25 | $81.9M | $580.0M | ||
| Q2 25 | $100.0M | $629.1M | ||
| Q1 25 | $85.8M | $698.6M | ||
| Q4 24 | $112.9M | $525.5M | ||
| Q3 24 | $119.7M | $585.0M | ||
| Q2 24 | $121.8M | $933.7M | ||
| Q1 24 | $111.1M | $1.0B |
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | $2.6B | $1.1B | ||
| Q2 25 | $2.6B | $1.1B | ||
| Q1 25 | $2.7B | $1.1B | ||
| Q4 24 | $2.6B | $1.1B | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.9B | — |
| Q4 25 | $-626.4M | $-99.3M | ||
| Q3 25 | $-548.7M | $-354.5M | ||
| Q2 25 | $-485.5M | $-305.5M | ||
| Q1 25 | $-446.1M | $-250.8M | ||
| Q4 24 | $-419.2M | $-139.6M | ||
| Q3 24 | $-288.4M | $-60.1M | ||
| Q2 24 | $-225.9M | $-1.6M | ||
| Q1 24 | $-276.8M | $68.3M |
| Q4 25 | $2.8B | $2.0B | ||
| Q3 25 | $3.0B | $1.3B | ||
| Q2 25 | $3.1B | $1.3B | ||
| Q1 25 | $3.1B | $1.3B | ||
| Q4 24 | $3.2B | $1.5B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.5B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-26.4M |
| Free Cash FlowOCF − Capex | $-86.8M | $-54.2M |
| FCF MarginFCF / Revenue | -33.5% | -19.3% |
| Capex IntensityCapex / Revenue | 27.5% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-135.5M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.7M | $-26.4M | ||
| Q3 25 | $5.5M | $-35.4M | ||
| Q2 25 | $16.3M | $-60.3M | ||
| Q1 25 | $-25.0M | $-62.7M | ||
| Q4 24 | $-23.6M | $-64.5M | ||
| Q3 24 | $795.0K | $-51.1M | ||
| Q2 24 | $8.0M | $-94.0M | ||
| Q1 24 | $-46.5M | $-30.3M |
| Q4 25 | $-86.8M | $-54.2M | ||
| Q3 25 | $-226.0K | $-45.8M | ||
| Q2 25 | $-3.6M | $-65.9M | ||
| Q1 25 | $-44.8M | $-67.1M | ||
| Q4 24 | $-131.6M | $-83.4M | ||
| Q3 24 | $-21.8M | $-55.3M | ||
| Q2 24 | $-22.9M | $-99.1M | ||
| Q1 24 | $-80.4M | $-37.2M |
| Q4 25 | -33.5% | -19.3% | ||
| Q3 25 | -0.1% | -17.3% | ||
| Q2 25 | -1.2% | -28.4% | ||
| Q1 25 | -16.2% | -33.0% | ||
| Q4 24 | -47.8% | -41.3% | ||
| Q3 24 | -7.9% | -28.9% | ||
| Q2 24 | -7.2% | -55.9% | ||
| Q1 24 | -26.5% | -22.1% |
| Q4 25 | 27.5% | 9.9% | ||
| Q3 25 | 2.1% | 3.9% | ||
| Q2 25 | 6.6% | 2.4% | ||
| Q1 25 | 7.2% | 2.2% | ||
| Q4 24 | 39.2% | 9.4% | ||
| Q3 24 | 8.2% | 2.2% | ||
| Q2 24 | 9.8% | 2.9% | ||
| Q1 24 | 11.2% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | -0.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AHT
| Occupancy | $190.2M | 73% |
| Food And Beverage | $51.8M | 20% |
| Hotel Other | $16.6M | 6% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
